Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.8 GBX
1.33%
Updated:
Apr 23, 2024
Fusion Antibodies PLC
Operating Income
Last
Value
3-Years CAGR
5-Years CAGR
|
Fusion Antibodies PLC
Operating Income Peer Comparison
Comparables:
ONT
O
ORPH
DXRX
ERGO
HVO
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Operating Income
£-3m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Operating Income
£-168.6m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Operating Income
£6.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Operating Income
£575k
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Ergomed PLC
LSE:ERGO
|
Operating Income
£20.7m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Operating Income
£10.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Fusion Antibodies PLC's Operating Income?
Operating Income
-3m
GBP
-3m
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Operating Income amounts to -3m GBP.
What is Fusion Antibodies PLC's Operating Income growth rate?
Operating Income CAGR 5Y
-16%
-16%
Over the last year, the Operating Income growth was -56%. The average annual Operating Income growth rates for Fusion Antibodies PLC have been -44% over the past three years , -16% over the past five years .
You don't have any saved screeners yet
